Abstract:Background: Recent policies have lessened restrictions around prescribing buprenorphine-naloxone (buprenorphine) for the treatment of opioid use disorder (OUD). The primary concern expressed by critics of these policies is the potential for buprenorphine diversion. However, the population-level effects of increased buprenorphine diversion are unclear. If replacing the use of heroin or fentanyl, use of diverted buprenorphine could be protective. Methods: Our study aim was to estimate the impact of buprenorphine diversion on opioid overdose using an agent-based model calibrated to North Carolina. We simulated the progression of opioid misuse and opioid-related outcomes over a 5-year period. Our status quo scenario assumed that 50% of those prescribed buprenorphine diverted at least one dose per week to other individuals with OUD and 10% of individuals with OUD used diverted buprenorphine at least once per week. A controlled prescription only scenario assumed that no buprenorphine would be diverted, while an increased diversion scenario assumed that 95% of those prescribed buprenorphine diverted and 50% of individuals with OUD used diverted buprenorphine. We assumed that use of diverted buprenorphine replaced the use of other opioids for that day. Sensitivity analyses increased the risk of overdose when using diverted buprenorphine, increased the frequency of diverted buprenorphine use, and simulated use of diverted buprenorphine by opioid-naïve individuals. Scenarios were compared on opioid overdose-related outcomes over the 5-year period. Results: Our status quo scenario predicted 10,658 (credible interval [CI]: 9699-11,679) fatal opioid overdoses. A scenario simulating controlled prescription only of buprenorphine (i.e., no diversion) resulted in 10,741 (9895-11,650) fatal opioid overdoses versus 10,301 (9439-11,244) within a scenario simulating increased diversion. Compared to the status quo, the controlled prescription only scenario resulted in a similar number of fatal overdoses, while the scenario with increased diversion of buprenorphine resulted in 357 (3.35%) fewer fatal overdoses. Even when increasing overdose risk while using diverted buprenorphine and incorporating use by opioid naïve individuals, increased diversion did not increase overdoses compared to a scenario with no buprenorphine diversion. Conclusions: A similar number of opioid overdoses occurred under modeling conditions with increased rates of buprenorphine diversion among persons with OUD, with non-statistical trends toward lower opioid overdoses. These results support existing calls for low- to no-barrier access to buprenorphine for persons with OUD.

Harm reduction for addictive consumption: When does it improve health and when does it backfire?

Commentary: Similarities and Differences Between Harm-Reduction and Substitute Addiction-- Implications for the Health Professions

Electronic cigarettes as a harm reduction strategy for tobacco control: A step forward or a repeat of past mistakes?

A qualitative exploration of harm reduction in practice by street-based peer outreach workers

Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine

What is the role of harm reduction when drug users say they want abstinence?

Harm reduction isn't enough: Introducing the concept of Mindful Consumption and Benefit Maximization (MCBM)

From harm reduction to drug user abstinence: a journey in drug treatment policy

Decision-making Deficits Are Still Present in Heroin Abusers after Short- to Long-Term Abstinence.

Punishment Induces Risky Decision-Making in Methadone-Maintained Opiate Users but Not in Heroin Users or Healthy Volunteers

From pain patient to junkie: An economic theory of painkiller consumption and its impact on wellbeing and longevity

Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of Competition

Addressing adolescent substance use with a public health prevention framework: the case for harm reduction

Should contingency management protocols and dissemination practices be modified to accommodate rising stimulant use and harm reduction frameworks?

Meeting people where they are: implementing hospital-based substance use harm reduction

Behavioral and Health Outcome Differences by Heroin or Methamphetamine Preference Among People in Rural US Communities Who Use Both Substances

The Role of Withdrawal in Heroin Addiction: Enhances Reward or Promotes Avoidance?

Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study

“No Good Choice”: What are the Issues of Having no Harm Reduction Strategies in Hospitals?

Harm Reduction for Injecting Opiate Users: an Update and Implications in China

Harm Reduction Treatment for Substance Use